Radiofrequency ablation in Von-Hippel-Lindau disease with bilateral renal cell carcinoma: a case report
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20222159Keywords:
VHL, Bilateral RCC, Radio frequency ablationAbstract
Von Hippel-Lindau (VHL) disease is a familial form of renal cell carcinoma which manifests as bilateral renal cell carcinoma. Radiofrequency ablation is a minimally invasive technique helps in treating renal cell carcinoma with renal function preservation. We reported a case of 29 years old male with bilateral renal cell carcinoma. We treated him with left radical nephrectomy and right side multifocal RCC with Radio frequency ablation. Radiofrequency ablation definitely have a role as alternative treatment modality to nephron sparing surgical procedure for small (<4 cm) localised RCC. Further studies are needed to assess its long-term efficacy.
Metrics
References
Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol. 2013;23:46-55.
Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer. 2010;116:3135-42.
Zagoria RJ, Pettus JA, Rogers M, Werle DM, Childs D, Leyendecker JR. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology. 2011;77:1393-7.
Zagoria RJ. Percutaneous image-guided radiofrequency ablation of renal malignancies. Radiol Clin North Am. 2003;41:1067-75.
Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ. Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. AJR Am J Roentgenol. 2003;180:1503-8.
Jemal A, Tiwari RC, Murray T. Cancer statistics. CA Cancer J Clin. 2004;54:8-29.
Latif F, Tory K, Gnarra J. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-20.
Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23:18-25.
Ljungberg B, Cowan NC, Hanbury DC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398-406.
Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003;226:417-24.
Poon RT, Ng KK, Lam CM. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg. 2004;239:441-9.
Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol. 2005;185:72-80.
Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 2007;189:429-36.
Farrell MA, Charboneau JW, Callstrom MR, Reading CC, Engen DE, Blute ML. Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2003;181:1315-7.
Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer. 2010;116: 3135-42.
Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int. 2014;113(3):416.
Zagoria RJ, Pettus JA, Rogers M, Werle DM, Childs D, Leyendecker JR. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology. 2011;77:1393-7.
Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001;166:6-18.
Lane BR, Gill IS. 7 years oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010;183:473-9.
Yossepowitch O, Bjartell A, Eastham JA. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008;179:2158-63.
